HUMANWELL HEALTHCARE (GROUP) CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.97 CNY | -2.25% |
|
-2.47% | -31.74% |
| Sales 2024 * | 26.7B 3.67B | Sales 2025 * | 28.87B 3.97B | Capitalization | 27.3B 3.75B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.54B 349M | Net income 2025 * | 2.96B 407M | EV / Sales 2024 * | 1.02 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.95 x |
| P/E ratio 2024 * |
10.9
x | P/E ratio 2025 * |
9.38
x | Employees | 17,676 |
| Yield 2024 * |
2.32% | Yield 2025 * |
2.73% | Free-Float | 61.2% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.25% | ||
| 1 week | -2.47% | ||
| Current month | -1.16% | ||
| 1 month | -12.07% | ||
| 3 months | -11.84% | ||
| 6 months | -31.79% | ||
| Current year | -31.74% |
1 week
16.75
17.58
1 month
16.7519.57
Current year
16.7525.75
1 year
16.7527.40
3 years
13.1529.13
5 years
9.4739.54
10 years
8.3539.54
| Managers | Title | Age | Since |
|---|---|---|---|
Jie Li
CHM | Chairman | 69 | 03-04-30 |
Xia Fei Deng
PSD | President | 61 | 98-02-28 |
Ya Jun Wu
DFI | Director of Finance/CFO | 54 | 05-03-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rui Zhou
BRD | Director/Board Member | 51 | 21-05-27 |
Yue Xin Du
CHM | Chairman | 66 | 05-03-27 |
Min Qi
BRD | Director/Board Member | 74 | 14-05-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.67% | 1 M€ | -23.91% | - | |
| 0.57% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 16.97 | -2.25% | 11,353,190 |
| 24-07-01 | 17.36 | +1.11% | 7,139,408 |
| 24-06-28 | 17.17 | -0.41% | 8,856,000 |
| 24-06-27 | 17.24 | -1.37% | 10,101,040 |
| 24-06-26 | 17.48 | +0.46% | 6,315,297 |
End-of-day quote Shanghai S.E., July 01, 2024
More quotes
Humanwell Healthcare Group Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company primarily operates its businesses through two segments. Pharmaceutical segment is mainly engaged in the research and development, production and sales of pharmaceutical products and the research and development, production and sales of medical device products, as well as the delivery, distribution and related businesses of pharmaceutical products, providing drugs, devices, medical equipment, reagents, consumables, health products, as well as technology and management services. The Company's products include chemical pharmaceutical preparations, chemical active pharmaceutical ingredients and others. Environmental Protection segment is primarily engaged in environmental protection engineering business.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.97
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.74% | 3.75B | |
| +55.55% | 816B | |
| +40.11% | 634B | |
| -6.83% | 351B | |
| +17.15% | 323B | |
| +7.09% | 293B | |
| +14.00% | 238B | |
| +1.39% | 222B | |
| +13.49% | 218B | |
| +7.87% | 167B |
- Stock Market
- Equities
- 600079 Stock
